Clinical trials: Huntington's Disease
Huntington Disease, Autobiographical Memory
Autobiographical Memory, Future Thought, and Eye Movements in Huntington's Disease
Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by progressively worsening motor, cognitive, psychiatric, and behavioral deficits.
- Trial name
- MAMOC-MH (NCT07409597)
- Testing
- neuropsychological tests, Eye tracker use
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Huntington Disease
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
Positron Emission Tomography (PET) is a functional imaging technique, which enables in vivo visualization of biological molecules expressed in human tissues.
- Trial name
- NCT05360082
- Testing
- [11C]UCB-J PET, [18F]SynVest-1 PET
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer's Disease, Amyotrophic Lateral Sclerosis
Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.
This is a prospective investigation of the effects of Laughter therapy (LT) on perceived stress, self-efficacy, mood and other wellness measures in people with the following neurological conditions: Alzheimer's disease…
- Conditions
- Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Brain Injury, Huntington's Disease
- Trial name
- NCT02750982
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Huntington Disease
Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Examine the effects of deutetrabenazine on functional speech and gait impairment
- Trial name
- NCT04713982
- Testing
- Deutetrabenazine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt University Medical Center
Huntington Disease
Resveratrol and Huntington Disease
The purpose of this study is to evaluate the therapeutic potential of Resveratrol on the caudate volume in HD patients, using volumetric MRI.
- Trial name
- REVHD (NCT02336633)
- Testing
- Resveratrol
- Where
- France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Huntington Disease
Evaluation of Three Tests to Assess Social Cognition in Huntington Disease
The goal of this observational study is to learn about the usefulness of a test of social functioning in persons with Huntington disease.
- Trial name
- NCT07253038
- Where
- Sweden
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Region Skane
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Huntington's Disease
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess…
- Trial name
- Pre-CREST-2X (NCT01411163)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Huntington's Disease
A Phase II Safety and Tolerability Study With SEN0014196
The principal aim of this study is to obtain safety and tolerability data when SEN0014196 is administered orally over 12 weeks to male and female patients with Huntington's Disease.
- Trial name
- NCT01521585
- Testing
- SEN0014196
- Where
- Germany
- Volunteers
- 144 people
- Sponsor
- Siena Biotech S.p.A.
Huntington Disease, Alzheimer Disease
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
This drug-drug interaction study is being conducted to evaluate the potential effect of Dimebon on the pharmacokinetics on dextromethorphan, a probe substrate of the cytochrome P450 2D6 (CYP2D6) enzyme, after multiple dose…
- Trial name
- NCT00788047
- Testing
- Dextromethorphan, Dimebon + Dextromethorphan
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington's Disease
PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease
Deep Brain Stimulation (DBS) of the Globus pallidus internus(GPi) is useful in the treatment of different forms of chorea, including Huntington's disease (HD).
- Trial name
- NCT02263430
- Testing
- Deep Brain Stimulation
- Volunteers
- 8 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Huntington's Disease
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
Huntington's disease (HD) is a genetic progressive fatal neurodegenerative disorder. In the western world it affects 5-10 persons per 100000. The main brain changes include the loss of brain cells in subcortical structures.
- Trial name
- FISCIP (NCT02551705)
- Testing
- functional Imaging
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Huntington Disease, Huntington's Dementia
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Trial name
- SAN-09611 (NCT05773196)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sanguine Biosciences
Huntington's Disease
Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease
OBJECTIVES: I. Correlate clinical outcome with cerebral glucose metabolism in patients with Huntington's disease (HD) and their at-risk relatives. II.
- Trial name
- NCT00004753
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Huntington's Disease (HD), Exergame
Comparison of Two Cognitive-Motor Rehabilitation Approaches Via Exergames: a Study of Cognitive, Motor and Behavioral Functions in Huntington's Disease Patients
Huntington's disease (HD) is a rare, hereditary neurodegenerative disorder. It generally manifests itself between the ages of 40 and 50, and results in motor impairment (choreic movements, balance disorders, gait disorders…
- Trial name
- CARE-MH (NCT06807892)
- Testing
- Synergistic management, Sequential management
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Angers
Huntington Disease
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
- Trial name
- NCT00146211
- Testing
- Ethyl-EPA (Miraxion™)
- Where
- 41 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- Amarin Neuroscience Ltd
Huntington's Disease
Exercise Effects in Huntington's Disease
Huntington's disease (HD) is an incurable and fatal disorder characterised by progressive degeneration of the basal ganglia and the cerebral cortex.
- Trial name
- NCT01879267
- Testing
- Exercise training
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Huntington's Disease
Exploring Computerised Cognitive Training for People With Huntington's Disease
Cognitive impairments, especially deficits of executive function, have been well documented as a core and early feature in Huntington's disease (HD).
- Trial name
- CogTrainHD (NCT02990676)
- Testing
- Computerised cognitive training
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cardiff University
Huntington's Disease
FuRST 2.0 Cognitive Pre-Testing
The FuRST 2.0 scale is being developed as a Patient Reported Outcome (PRO) with information coming directly from the Huntington's Disease Gene Expansion Carrier (HDGEC) and companion through self-report.
- Trial name
- NCT02881931
- Testing
- FuRST 2.0
- Where
- 4 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- CHDI Foundation, Inc.